The Powered by Affymetrix Program enables commercial entities to license GeneChip® technology to develop microarray products for applications in diagnostics, forensics, animal testing, industrial testing, food testing, and more. GeneChip technology enables Powered by Affymetrix Partners to develop innovative products and robust solutions.
Developed and marketed by you. Powered by Affymetrix.
Affymetrix has made a decade-long investment in optimizing our GeneChip® System to become the microarray platform of choice for complex genomic analysis. Now, we are making this breakthrough technology available to companies like yours, so you can create tailored products and services for your unique markets and customers, and realize unprecedented opportunity.
By adopting the GeneChip® brand platform to create new biological assays for human diagnostics, animal, plant, and microbial testing applications, you can develop the next generation of high-value, innovative assays for the diagnostics and industrial markets.
Affymetrix ensures more than mere technology adoption. Our Powered by Affymetrix™ Program is a relationship-based business model, providing you with the support and collaboration every step of the way to incorporate the GeneChip System as part of your assays and tests. From discovery to manufacturing, we have optimized our processes to facilitate your success.
Access to genetic information is paving the way to routinely answering complex biological questions. And Affymetrix is enabling the age of microarray-based tools and applications. Our proven technology platform and integrated system have been engineered to flexibly adapt to your unique market opportunities.
Contact Affymetrix today to learn more Clinical Diagnostics: email@example.com
One System. Multiple Applications. Infinite Possibilities.
The GeneChip® System offers multiple dimensions of flexibility for developing commercial assays and tests. Supporting both DNA and RNA analysis, this integrated platform provides the versatility to develop virtually any type of genetic or genomic assay with accurate, reproducible results. And regardless of the size or magnitude of your genetic analysis, the GeneChip System may be easily customized to fit the specific needs of your markets.
The Powered by Affymetrix™ program provides a standardized platform for developing new diagnostic testing and monitoring products. Our microarray platform is fully scalable for investigating specific genetic targets or an entire genome of human, plant, animal, or microbial systems. With the comprehensive data that the GeneChip System provides, you can readily identify and validate novel signatures for understanding the pathways and genetic characteristics of your targets, and develop novel applications for bringing value to your markets of interest.
Additionally, the Affymetrix GeneChip Dx System, consisting of the GeneChip® Scanner 3000Dx, Fluidics Station 450Dx, AutoLoaderDx, and GeneChip® Operating Software Dx, has achieved CE marking and FDA clearance for in vitro diagnostic use, which may help your validated assay solutions successfully penetrate targeted diagnostic and industrial markets with agility and confidence.
Partnership for Success
Using the Powered by Affymetrix Program to develop your microarray-based solutions is a true partnership, with a powerful fusion of your testing and market expertise and our experience in pioneering microarray products. This unique program is designed with optimized processes that can help you successfully bring your microarray-based solutions to market.
With the GeneChip platform, your assays can be developed, approved, and marketed on the same, cost-efficient platform, eliminating technology transfer challenges during development and validation. Our system, thus, offers you a unified platform for seamlessly and efficiently developing valuable assay products. From discovery to market development, Affymetrix collaborates with you every step of the way.
Developing your assays on one platform start-to-finish can ensure efficiency, validation, and rapid time-to-market, while saving valuable time and resources.
2. Array Manufacturing
Our industrial-scale manufacturing facilities offer you the flexibility to develop arrays to your exact specifications, such as the number of features or targets you require on each array.
Affymetrix has already developed the necessary instrumentation for microarraybased tests, so you can easily provide full solutions to your markets.
4. Regulatory Compliance
Having already met the requirements for European Union CE marking and United States FDA 510(k) clearance, the GeneChip Dx System is positioned to assist in the development of diagnostic tests.
5. Market Development
From expert technical support to the development of strategic marketing programs, Affymetrix can partner with you to ensure rapid technology adoption of your microarray-based assays.
Current Powered by Affymetrix Partners
Almac partners with the biopharmaceutical industry to provide biomarker discovery and development solutions ranging from pre-clinical biomarker discovery to full companion diagnostic development, biomarker clinical trial management and clinical test delivery from their CLIA lab. Almac has an expert team with a wide range of experience. Almac has a portfolio of proprietary discovery arrays and extensive experience and expertise working with formalin fixed paraffin embedded (FFPE) tissue. Almac utilizes this expertise, experience and innovative technology in developing diagnostics for partners and in developing Almac's own pipeline of molecular diagnostics.
As a major player in the field of in vitro infectious disease diagnostics, Biomerieux designs, develops, manufactures, and markets reagents and automated instruments for medical analyses and product quality control in the agri-food, cosmetics, and pharmaceutical industries.
Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer screening and cancer specialty applications such as monitoring and classification.
IPSOGEN is a molecular diagnostic company focused on the development and commercialization of innovative diagnostic products to guide treatment options in cancers. The CE-marked MapQuant Dx Genomic Grade* is the very first molecular diagnostic test to accurately measure tumor grade, a consensus indicator of tumor proliferation, risk of metastasis and response to chemotherapy.
*MapQuant Dx Genomic Grade is not available in the United States
Medical Prognosis Institute
Medical Prognosis Institute (MPI) is a dedicated Affymetrix Service Provider that provides world-class bioinformatics services with quality assurance and fast turnaround. MPI also develops companion diagnostics for cancer drugs from biotech and pharma and prognostic assays for cancer. Based in the Medicon Valley area in Denmark, MPI has experience with global clinical trials and regulatory authorities.
PathGEN Dx is a spin-off company founded by scientists from the Genome Institute of Singapore, under the Agency for Science, Technology, and Research (A*STAR), and is a global solutions provider in the research, biosurveillance, and diagnostic markets. PathGEN conducts research and development for infectious disease diagnostics, biosurveillance, and epidemiology. PathGEN's proprietary PathGEN® PathChip Kit can efficiently detect the presence of more than 70,000 viral and bacterial genomes from a wide variety of human samples, annotate the genomic information, and identify co-infecting pathogens.
Pathwork Diagnostics, Inc., based in Redwood City, CA, develops and commercializes innovative, high-value molecular diagnostics for oncology. The company's Pathwork® Tissue of Origin Test is a microarray-based gene expression test that aids in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers. It is the only FDA-cleared and Medicare-covered molecular test of its kind. The company provides the Tissue of Origin Test through its CLIA-certified, CAP-accredited laboratory.
Roche is a leading healthcare company with a broad spectrum of innovative medical solutions. For more than 100 years, Roche has been active in the discovery and development, manufacturing and marketing of novel healthcare solutions. Learn more about the AmpliChip CYP 450, the world's first microarray-based pharmacogenomic test FDA cleared for clinical use.
Signature Diagnostics AG
Signature Diagnostics, a biotechnology company based in Potsdam, Germany, is positioned in oncogenomics and clinical oncology diagnostics. The company is dedicated to the development of novel prognostic gene signatures for predicting outcome and drug response in cancer patients. Signature's lead product is Detector C*, which is a blood-based screening test for the early detection of colorectal cancer.
*Detector C is not available in the United States
Skyline Diagnostics BV
Skyline Diagnostics develops and markets microarray-based diagnostic tests using molecular signatures for personalized medicine in oncology. With its infrastructure, expertise, and access to large collections of well-defined clinical samples, Skyline is an excellent partner for discovery, development, and commercialization of new diagnostic assays and devices. Skyline's leading product is the AMLprofiler*, a CE marked in vitro diagnostic test that determines relevant diagnostic and prognostic markers for Acute Myeloid Leukemia in a single microarray-based assay.
*AMLprofiler is not available in the United States
Sysmex is a global diagnostics company headquartered in Kobe, Japan, which provides instruments, reagents, laboratory information system products, and after-sales support for hematology and urinalysis testing. Sysmex has expanded its scope of business to include fields such as cancer diagnostics.
TessArae designs and develops custom turnkey assays for targeted sequencing in human genetic disease and infectious disease research applications. Their proprietary TessArae GeneCipher assay design platform provides the expertise and base calling algorithms with associated confidence metrics to enable the simultaneous detection and identification of hundreds of mutations in human genes, or hundreds of viral, bacterial, or fungal pathogens, in a single assay in less than 24 hours. TessArae delivers the power to perform complex genetic disease or infectious disease research that is faster, easier, and less expensive than with Sanger or next-generation sequencing technologies, while eliminating the labor-intensive bioinformatics burden.
Delivering the Promise of Personalized Medicine Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians and patients with high-value in vitro diagnostic oncology products. Veridex's products will significantly benefit patients through earlier disease detection, and will enable personalized strategies to improve patient management and outcomes.